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Abstract The hypothesis that specific protein kinase C (PKC)
isoforms regulate dopamine transporter (DAT) function was
tested in Xenopus laevis oocytes expressing human (h)DAT.
Activation of conventional PKCs (cPKCs) and novel PKCs
(nPKCs) using 10 nM phorbol 12-myristate 13-acetate (PMA)
significantly inhibited DAT-associated transport currents.
This effect was reversed by isoform-non-selective PKC inhibi-
tors, selective inhibitors of cPKCs and NPKC, and by Ca2+
chelation. By contrast, the OPKC translocation inhibitor peptide
had no effect on PMA-induced inhibition of hDAT transport-
associated currents. Thus, the primary mechanism by which
PMA regulates hDAT expressed in oocytes appears to be by
activating cPKC(s). ß 2002 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Dopamine (DA) transporter (DAT) belongs to a superfam-
ily of Na/Cl3-dependent neurotransmitter transporters that
also includes transporters for serotonin, norepinephrine, and
Q-aminobutyric acid (GABA) [23]. DAT is crucial for clearing
DA from the extracellular space. DAT transports substrates
such as DA against their electrochemical gradient by coupling
to the inward transport of DA with two Na and one Cl3
ions [5,10,12]. Thus, at negative membrane potentials (3120
to 320 mV) a net positive inward current is produced by
substrate transport. In Xenopus oocytes expressing human
(h)DAT, this inward current re£ects real-time measurements
of transporter function [18].
It has been well established that protein kinase C (PKC)
activation inhibits DAT function by decreasing the number of
functional transporters on the cell surface. In support of this
concept, functional studies have consistently demonstrated
PKC activation causes a decrease in DAT maximal transport
velocity (Vmax) and DAT-associated transport currents with
no change in substrate a⁄nity (KM) [1,2,6,9,13,16,20,24,25].
Furthermore, several experimental approaches have been
used to show a PKC-induced redistribution of DAT away
from the cell surface membrane [2,13,16,24].
There are at least 12 PKC isoforms of PKC that are divided
into three subfamilies based on structure and function [14].
Conventional PKC (cPKC) isoforms (K, LI, LII, Q) have a
putative Ca2-binding site and are Ca2-sensitive. Novel
PKC (nPKC) isoforms (N, O, R, a) lack a putative Ca2-bind-
ing site and are Ca2-independent. Both cPKCs and nPKCs
are activated by phorbol esters such as phorbol 12-myristate
13-acetate (PMA). Atypical PKC isoforms (j, S, V, W) are
Ca2-insensitive and are not activated by phorbol esters. Sev-
eral pharmacological inhibitors have been developed to inves-
tigate the role of PKC experimentally. For example, cheler-
ythrine and bisindolylmaleimide (BIS) I are structurally
dissimilar, and both inhibit all PKC isoforms. Go« 6979 selec-
tively inhibits the Ca2-sensitive cPKC isoforms (IC50 = 2.3^
7.9 nM) [11]. Rottlerin is thought to be a selective inhibitor
for NPKC (IC50 = 3^6 WM). However, rottlerin also inhibits
Ca2/calmodulin kinase III at similar concentrations
(IC50 = 5.3 WM) and is active at 10-fold higher concentrations
against recombinant cPKC isoforms (IC50 = 30^42 WM) [4].
PKC subcellular localization and function involve the binding
of PKC to isoform-speci¢c receptors for activated C kinases
(RACKs) [17]. Inhibition of this interaction disrupts substrate
phosphorylation and function of PKC isoforms. For example,
the OPKC translocation inhibitor peptide binds the OPKC-
speci¢c RACK and inhibits PMA-induced OPKC activity
[8].
It is not yet known which of these PKC isoform(s) contrib-
ute(s) to DAT regulation. In the present study, pharmacolog-
ical and biochemical approaches were used to investigate this
question in hDAT-expressing oocytes. Western blot analysis
using Xenopus oocytes has demonstrated the presence of
cPKC and nPKC isoforms including K-, LI-, LII-, Q-, N-, and
OPKC [7,21]. The atypical PKC isoforms were not considered
in this study because phorbol esters that mediate hDAT reg-
ulation do not activate these isoforms.
2. Materials and methods
2.1. Materials
BIS I (2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-
3yl)-maleimide), BIS V (2,3-bis(1H-indol-3-yl)-N-methylmaleimide),
chelerythrine chloride, Go« 6979 (12-(2-cyanoethyl)-6,7,12,13-tetrahy-
dro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole), PMA,
OPKC translocation inhibitor peptide and rottlerin were purchased
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from Calbiochem (La Jolla, CA, USA). DA was purchased from
Sigma (St. Louis, MO, USA).
2.2. Animals and oocyte preparation
Oocyte positive Xenopus laevis frogs were purchased from Xenopus
I (Ann Arbor, MI, USA). All animal use procedures were in accor-
dance with the National Institutes of Health Guide for the Care and
Use of Laboratory Animals and were approved by the Institutional
Animal Care and Use Committee, University of Colorado Health
Sciences Center. Stage V and VI oocytes were defolliculated by gentle
shaking in OR2 bu¡er (82 mM NaCl, 2.5 mM KCl, 1.0 mM MgCl2,
5 mM HEPES, pH 7.5) containing 1.4^2.0 mg/ml collagenase B
(Boehringer Mannheim, Indianapolis, IN, USA) for approximately
2 h at room temperature.
2.3. DAT expression
Capped cRNA was transcribed from a linear oocyte expression
vector pOTV containing the 1.9 kb hDAT cDNA insert [18] using
mMessage mMachine with T7 polymerase (Ambion, Austin, TX,
USA). Oocytes were injected with water-diluted cRNA (V10 ng)
and maintained at room temperature in frog Ringer’s bu¡er (FRB;
96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2 and 5 mM
HEPES, pH 7.5) supplemented with 2.5 mM sodium pyruvate, 0.5 mM
theophylline, 100 U/ml penicillin, 100 Wg/ml streptomycin and 50 Wg/
ml gentamicin for 3^4 days.
2.4. Two-electrode voltage-clamp electrophysiology
Currents were measured in oocytes using two-electrode voltage-
clamp. Microelectrodes were ¢lled with 3 M KCl [18]. A Warner
OC-725B ampli¢er (Warner Instruments, Hamden, CT, USA) was
used with a DigiData 1200 interface. pClamp6 software (Axon Instru-
ments, Foster City, CA, USA) was used to control stimulation pa-
rameters, for data acquisition and for analysis. MacLab data acqui-
sition software (AD Instruments, Castle Hill, Australia) and a
MacLab/2e interface were used to monitor experiments. Currents
were low-pass-¢ltered at 100 Hz and digitized at 2048 Hz.
Oocytes were superfused in a 0.5 ml bath at approximately 2 ml/
min with normal FRB (unless otherwise indicated) at room temper-
ature. Oocytes were voltage-clamped at 360 mV and then subjected
to a series of 400 ms steps in membrane potential ranging from 3120
mV to +40 mV in 10 mV increments. Currents were recorded before
and again after a 1 min superfusion with 10 WM DA. Steady-state
currents were measured as the average of the last 100 ms of each
voltage step. Inward currents were calculated by performing o¡-line
subtraction of currents measured in the presence of DA from current
measured in the absence of DA (IDA3Ibuffer). E¡ects of PKC activa-
tion on DA-induced currents were determined after superfusing oo-
cytes with FRB containing 10 nM PMA for 3 min followed by a
10 min wash with FRB. In some oocytes superfusion with PMA
was preceded by a 3 min superfusion with a PKC inhibitor, and the
inhibitor was present during PMA superfusion. Subsets of oocytes
were injected with 32 nl of selective PKC inhibitor to achieve the
intracellular concentration indicated in Section 3, assuming the vol-
ume of an oocyte to be 1000 nl. Injected oocytes were allowed to
recover until the resting membrane potential stabilized (approximately
10 min) before measuring hDAT-mediated currents. These injections
had no e¡ect on DA-induced currents.
2.5. Data analysis
Currents from each oocyte were normalized to the control hDAT-
mediated current measured at 3120 mV. For statistical analysis,
transport-associated currents were compared at 360 mV. This mem-
brane potential was chosen to approximate the resting potential of a
neuron. Statistical signi¢cance was determined by unpaired Student’s
t-test with a signi¢cance criterion of P6 0.05.
3. Results and discussion
3.1. PMA reduces hDAT-mediated currents via PKC activation
It has been well documented that PMA decreases DAT
function via redistribution of the transporter away from the
cell surface [1,2,6,9,13,16,20,24,25]. These previous studies in-
clude one from our laboratory that showed that PMA expo-
sure to hDAT-expressing oocytes results in attenuation of
hDAT-mediated currents [25]. In the present study, the
PKC isoform(s) involved in hDAT regulation were investi-
gated. Oocytes expressing hDAT were superfused for 3 min
with a near-maximal PMA concentration (10 nM) [25] and
then washed with FRB for 10 min. DAT substrate trans-
port-associated currents predominate at 3120 to 320 mV
while a DAT-associated leak current is evident at 320 to
Fig. 1. E¡ect of PMA and PKC inhibitor pretreatment on hDAT-
mediated currents. Two-electrode voltage-clamp recording was used
to measure hDAT-associated currents as described in Section 2.
Current^voltage (I^V) relationships are shown for hDAT-mediated
currents elicited by superfusion with a maximally e¡ective concen-
tration of the hDAT substrate DA (10 WM). After control DA-in-
duced currents were measured, oocytes were superfused with FRB
containing drugs: (A) 10 nM PMA, (B) 1 WM chelerythrine fol-
lowed by 10 nM PMA, or (C) 1 WM BIS I followed by 10 nM
PMA. Oocytes were superfused with PKC inhibitors for 3 min and
then inhibitor plus PMA for 3 min. DA-induced currents were mea-
sured again 10 min following drug treatment. Data represent
mean þ S.E.M. for seven to nine oocytes from three batches of oo-
cytes. At 360 mV, unpaired t-tests showed P6 0.05 for control vs.
PMA only in A.
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+40 mV [18]. This leak current shows more variable e¡ects
and will not be addressed here. Similar to our previous ob-
servations, PMA treatment decreased hDAT transport-associ-
ated currents induced by a maximally e¡ective DA concentra-
tion (10 WM) (Fig. 1A). For example, at 360 mV the hDAT-
associated current after PMA treatment was 42.5% of the
control current (Fig. 1A).
Two structurally dissimilar isoform-non-selective PKC in-
hibitors, namely chelerythrine and BIS I, were used in con-
junction with PMA to con¢rm that PMA-mediated induced
attenuation of hDAT transport-associated currents was occur-
ring via PKC activation. In oocytes pretreated with either 1
WM chelerythrine or 1 WM BIS I followed by PMA, the PMA-
induced attenuation of hDAT transport-associated currents
was abolished, compared to PMA pretreatment alone (Fig.
1B,C). An inactive analog of BIS I, BIS V, had no e¡ect on
hDAT-mediated currents, suggesting BIS I blocks the e¡ects
of PMA by selectively inhibiting PKC activation (data not
shown). None of the inhibitors when used alone in this study
a¡ected the oocyte resting membrane potential or control
currents (data not shown).
3.2. E¡ects of cPKC inhibition on PMA-induced attenuation of
hDAT-mediated currents
Several lines of evidence suggest that Ca2-dependent
cPKCs contribute to PMA-mediated hDAT regulation. First,
the selective cPKC inhibitor, Go« 6976, blocked inhibition of
hDAT transport-associated currents by PMA. Go« 6976 (32 nl;
¢nal concentration 100 nM) was injected directly into oocytes,
and the oocytes were allowed to recover until the resting po-
tential stabilized before currents were recorded. As seen in
Fig. 2A, the e¡ect of PMA was abolished in Go« 6976 pre-
treated oocytes compared with oocytes in the absence of Go«
6979 (see Fig. 1A). At 360 mV the hDAT-associated current
was 97.2% of control current. Go« 6979 was more e¡ective
when injected directly into the oocyte compared with super-
fusion, suggesting limited permeability into the oocyte (data
not shown).
Second, the attenuation on hDAT transport-associated cur-
rents by PMA was reversed in the presence of EGTA (ethyl-
enebis(oxyethylenenitrilo)tetraacetic acid), a Ca2 chelator
(Fig. 2B), suggesting that the e¡ect of PMA on hDAT func-
Fig. 2. E¡ect of cPKC inhibition on PMA-induced inhibition of
hDAT-mediated currents. See Fig. 1 for experimental details. DA-
induced currents are shown before (control) and after 3 min super-
fusion with 10 nM PMA. See Fig. 1A for control response to PMA
alone. A: Go« 6976 (32 nl; ¢nal concentration 100 nM) was injected
directly into oocytes before current measurements. B: Oocytes were
superfused with Ca2-free OR2 bu¡er containing 0.5 mM EGTA
throughout current measurements. Data represent mean þ S.E.M.
for six to nine oocytes from three batches of oocytes.
Fig. 3. E¡ect of nPKC inhibitors on PMA-induced inhibition of
hDAT transport-associated currents. See Fig. 1 for experimental de-
tails. DA-induced currents are shown before (control) and after
3 min superfusion with 10 nM PMA. See Fig. 1A for control re-
sponse to PMA alone. In A and B, after control DA-induced cur-
rents were measured, oocytes were superfused with FRB containing
(A) 1 WM or (B) 10 WM rottlerin followed by PMA. Drug treatment
included superfusion with rottlerin for 3 min followed by a 3 min
exposure to PMA and rottlerin. DA-induced currents were mea-
sured again 10 min following drug treatment. C: 32 nl (8 ng) OPKC
translocation inhibitor peptide was injected directly into hDAT-ex-
pressing oocytes prior to current measurements. Data represent
mean þ S.E.M. for seven to nine oocytes from three batches of oo-
cytes. At 360 mV, unpaired t-tests showed P6 0.05 for control vs.
PMA in A and C.
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tion is Ca2-dependent. The fact that the e¡ect of PMA was
completely reversed in the presence of the cPKC inhibitor Go«
6976 or in the absence of Ca2 suggests not only that cPKC
isoforms are involved in PMA-mediated hDAT regulation,
but also that they may be exclusively responsible for PMA-
mediated decrease in hDAT transport-associated currents.
3.3. E¡ects of nPKC inhibitors on PMA-induced attenuation of
hDAT-mediated currents
Rottlerin is thought to selectively inhibit the NPKC isoform
[4]. In oocytes that were pretreated with rottlerin followed by
PMA, the PMA-induced attenuation of hDAT transport-as-
sociated currents was reversed in a concentration-dependent
manner, and the e¡ect of PMA was completely blocked by 10
WM rottlerin (Fig. 3A,B; refer to Fig. 1A for control response
to PMA). These results suggest the NPKC isoform also con-
tributes to PMA-mediated hDAT regulation. However, this
may not be the case as several groups have reported that
rottlerin inhibits other kinases including cPKCs [3,4,22]. It is
important to note that inhibitor selectivity studies were per-
formed in puri¢ed bovine and human PKC preparations while
the present experiments were performed in Xenopus oocytes
expressing native amphibian PKC isoforms. Thus, the potency
of these inhibitors may di¡er from that reported in the liter-
ature, and it is plausible that rottlerin inhibits cPKC isoforms
in this preparation. Furthermore, the fact that two di¡erent
methods used to inhibit cPKC activity reversed PMA-medi-
ated hDAT inhibition suggests that NPKC cannot be com-
pletely responsible for hDAT regulation. Thus, one interpre-
tation is that rottlerin reversed the e¡ect of PMA on hDAT-
associated currents by inhibiting cPKC isoforms. It is also
possible that both cPKC and NPKC isoforms act as a cascade,
but it seems much less likely that a PKC substrate would
phosphorylate another PKC isoform. It is not plausible that
the cPKC and NPKC isoforms substitute for one another or
that either may be part of cascades that converge. If this were
the case, activation of cPKCs and nPKCs followed by selec-
tive blockade would not have resulted in complete reversal of
PKC activation.
Activation and translocation of PKC can occur via the
binding of the PKC isoform to speci¢c RACKs. When a
OPKC translocation inhibitor peptide (8 ng) was injected di-
rectly into hDAT-expressing oocytes, PMA-mediated hDAT
transport-associated currents were unaltered, suggesting that
OPKC does not contribute to PKC regulation of hDAT (Fig.
3C).
Western blot analysis has con¢rmed the presence of cPKCs
(K, LI, LII, and Q) in dopaminergic brain regions in rat includ-
ing the nucleus accumbens, striatum, substantia nigra, and
ventral tegmental area [19]. Immunostaining has revealed
NPKC expression in rat substantia nigra [15]. Thus, it is rea-
sonable that these PKC isoforms regulate DAT function and
therefore synaptic DA levels in the brain. More selective in-
hibitors are needed before it can be determined precisely
which cPKC isoform(s) regulate(s) DAT. It is also interesting
to note that Na/Cl3-dependent transporters for serotonin,
norepinephrine, and GABA are inhibited by PKC activation
[23]. Future studies should reveal if the same PKC isoforms
that regulate DAT function also regulate these transporters or
if distinct isoforms regulate each transporter.
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